| Prev Close | 95.94 |
| Day Low/High | 94.06 / 96.03 |
| 52 Wk Low/High | 62.55 / 101.28 |
AbbVie, Inc. (ABBV)
94.70
1.20
1.30
NYSE
| Exchange | NYSE |
| Shares Outstanding | 1762.34B |
| Market Cap | 169.08B |
| P/E Ratio | 16.92 |
| Div & Yield | N.A. (N.A) |
I Believe AbbVie and Allergan Need Each Other
With no other bidder expected to emerge, this is a high risk arbitrage play.
Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
AbbVie Is Likely to Decline as Investors Digest Its Takeover Announcement
Let's look closer at the charts and indicators of ABBV.
AbbVie Fizzles, Gold, Bitcoin and (Some) Biotech Sizzles
AbbVie is dropping on Allergan deal announcement, momentum is weak outside certain pockets.
A Six-Pack of Biotech Best Bets
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
Earnings, Earnings and More Earnings, Facebook Results: Market Recon
As we have seen so far, in terms of market reaction, there is great reward at the point of sale in beating expectations.
Are These Stocks the Best of the Best?
Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.
5 Attractive Ways to Invest in Oncology
Experts offer their top stock ideas in oncology detection and treatment.
Why Risk-On Is In Vogue, Updating Zuora: Market Recon
China's central bank announced a bill swap mechanism late Thursday aimed at slowing down the nation's economic slowdown.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun
And it is happening not a moment too soon.
3 Key Bear Market Rules, 5 Bargain Buys and a Monthly Dividend Portfolio
Dow Theory presents tips for surviving a bear market, some top year-end stock bargains and a simple strategy for monthly income.
Nibble on This Bearish Strategy in Shake Shack: Market Recon
SHAK beat expectations for both EPS and revenue, but same-store sales decreased. Here is how I would play it.
Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken
Once the safest stocks in the book, the big-cap drug companies are now toxic.
Be Ready to Ride the Dividend on Gilead Sciences
There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.
Biotechs: Adding to Radius Health, Flexion
This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.
Amazon Could Rise Another 15% From Here: Market Recon
This stock is still going wild after earnings.
Galmed Soars on Encouraging Trial Results
Markets have perked up just a tad across the board since our last update. As mentioned in an earlier post, Galmed Pharmaceuticals is the second small-cap NASH (nonalcoholic steatohepatitis) play that has soared over the past week. The shares are up ...
When the Stock Is the Only Option
Options spreads aren't tradable with some small biotechs, making shares the only way to play.
Surveying the M&A Landscape in Biotech
Who might be in play in the quarters ahead?
4 Keys to Staying Alive in Tough Markets -- And How I'm Playing 3 Big Tech Names
KLA-Tencor, Microsoft and Intel all report earnings after the close Thursday.
Here's My Take on Biotech Stocks
I think M&A activity will pick up markedly going forward across the industry.
Amazon and Bank of America Are 2 of 16 Stocks Poised to Change Direction
These names are displaying signs of either bullish or bearish reversal patterns over the past week.
Some Quick Observations
Markets have improved somewhat in the past 90 minutes. The Dow and S&P 500 are now in the black with other major indices nearing even. Some quick observations about some stocks with less than two hours left to end the week. AbbVie clawing back a tad...
